Vol. 23/No. 12 | OncologyLive

Radioligand Therapy Boosts Survival in mCRPC

June 21, 2022


The prostate specific membrane antigen-targeting therapy, lutetium Lu 177 vipivotide tetraxetan, was approved by the FDA for patients with metastatic castration-resistant prostate cancer in March.

A Molecular Revolution Is Underway in Thoracic Oncology

June 20, 2022

Targetable alterations including BRAF V600E, EGFR exon 20 insertions, KRAS G12C mutations, MET exon 14 alterations, NTRK and RET rearrangements have taken up recent focus for investigators as data are pushing novel agents through the regulatory processes.

Markman Highlights Key Areas of Investigation in Oncology

June 19, 2022

Maurie Markman, MD, offers expert insights on the hurdles facing community oncologists, the uptake of biomarkers in the clinic, and an overview of what to look forward to in his area of expertise: gynecologic oncology.

Adjuvant and Neoadjuvant Treatments Chart New Course in Advanced RCC

June 17, 2022

A panel of kidney cancer experts discuss how therapeutic strategies in the neoadjuvant and adjuvant settings are affecting outcomes and how treatment selection in the first line has shifted approaches in the second and later lines of therapy.

Efforts Are Needed to Address the Enigmatic Rise of Young-Onset Gastrointestinal Cancers

June 16, 2022


Despite a steady decline in incidence and mortality rates of many cancers among older individuals in the United States and other high-income countries, an alarming rise in young-onset gastrointestinal cancers has simultaneously occurred.